In patients with obesity, how should sedation dosing be approached?

• A. Dosing should be carefully titrated with consideration of pharmacokinetics and airway challenges
• B. Dosing should be fixed and identical to non-obese patients
• C. Dosing should be avoided entirely
• D. Dosing should always be doubled

Answer: (D)

In obesity, sedation dosing must be carefully titrated with attention to how altered pharmacokinetics and airway anatomy affect drug effect. Obesity changes how drugs distribute, are metabolized, and cleared, and it raises the risk of airway problems during sedation. Lipophilic medications tend to have a larger volume of distribution in patients with more adipose tissue, which can prolong both onset and duration of effect if given in a fixed or proportional way. Sedatives and opioids can depress respiration more readily in this population, especially in those with obstructive sleep apnea or reduced cardiopulmonary reserve, so dosing must be individualized and advanced slowly with close monitoring.

Practically, this means starting at lower-than-expected doses and titrating to the desired effect, rather than relying on a fixed dose or simply scaling by body weight. Choose dosing strategies that reflect the drug’s properties and the patient’s physiology—some drugs are dosed by ideal body weight or adjusted body weight rather than actual body weight to avoid oversedation, while others require careful consideration of altered clearance. Use objective measures of sedation depth and continuous monitoring, and be prepared for a longer recovery and a heightened need for airway vigilance, including having airway equipment and reversal agents readily available. This approach targets safe, effective sedation while minimizing respiratory compromise and prolonged recovery.

Dosing everyone the same or doubling doses ignores how obesity changes drug behavior and airway risk, so those strategies are not appropriate.